The development of new therapeutics in recent months has not yet translated into a reduced death rate for patients with COVID-19.

In the spring the death rate was five to six percent, a rate attributed to limited testing.  Since testing became more widely available during the summer, however, the death rate has fallen to approximately 1.7 percent but has remained at that level despite the introduction of new ways to treat COVID-19.

Learn more about the new treatments, their impact on care, and the prospects for their eventual impact on COVID-19 death rates in the Washington Post article “Coronavirus survival rates in the United States haven’t improved since the summer.”